Windtree Therapeutics Faces Nasdaq Delisting After Failed $200 Million Fundraising

Windtree Therapeutics plans to raise up to $200 million for a BNB treasury but faces delisting from the Nasdaq. Key points include:

The Nasdaq will suspend trading of Windtree shares on August 21 due to failure to meet the $1 minimum bid price.
Windtree may transition to over-the-counter trading under the symbol "WINT," without guaranteed success.
The company previously announced a $60 million securities purchase agreement with Build and Build Corp., aiming to expand to $200 million.
Shares surged over 20% following the initial announcement but fell to 48 cents before the delisting news.
Following the delisting order, shares dropped nearly 80%, closing at 11 cents.

This situation limits Windtree's visibility and institutional reach compared to other companies like Michael Saylor’s strategy with bitcoin.